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Abstract 
Chronic renal failure (CRF) is a widespread medical problem commonly accompanied by a 
hypoproliferative anemia (“renal anemia”) due to erythropoietin deficiency. Anemia greatly 
contributes to reduced quality of life (Hr-QoL) and high morbidity and mortality in CRF 
patients. Recombinant human erythropoietin (rHu-Epo) was introduced to medical practice 
some 20 years ago. It enables correction of anemia (hemoglobin levels, Hb) with dramatic 
immediate (Hr-QoL improvement) and long-term effects (reduced morbidity and mortality). 
Newer experimental data suggest that long-term benefits could be due not only to 
antianemic effect, but also to a direct organoprotective effect of (rHu)-Epo mediated 
through a receptor complex different from the “erythropoietic” erythropoietin receptor. 
During the last decade, two alternative treatments for renal anemia have been approved: 
darbepoetin and CERA. Both are direct agonists of the “erythropoietic” receptors and both 
were derived from rHu-Epo. Molecularly, they differ from rHu-Epo in that they are much 
larger molecules (darbepoetin is genetically modified rHu-Epo with a higher sugar content 
and CERA is pegylated rHu-Epo) with lower affinity for the erythropoietin receptor but with a 
longer circulating time. In terms of renal anemia correction, they are non-inferior to rHu-Epo 
and allow for less frequent dosing. They have never been compared to rHu-Epo regarding 
the long-term outcomes. It is hypothesized that regarding the long-term outcomes 
(morbidity, mortality), rHu-Epo might be superior to those larger molecules. The hypothesis 
is based on two types of observations. First, experimental data emphasize the role of small, 
erythropoietically less valuable rHu-Epo isoforms in its organoprotective effects. Second, 
clinical observations suggest that rHu-Epo enables for less variable Hb correction than the 
larger molecules, and pronounced within-subject Hb variability has been suggested as an 
independent predictor of poor long-term outcomes of renal anemia management. 
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Introduction 
Virtually all patients suffering from chronic renal failure (CRF) eventually become anemic. 
The condition is termed “anemia associated with CRF” or simply “renal anemia”. Although it 
is multifactorial in nature, the major etiological factor of this normochromic normocytic 
anemia is erythropoietin (Epo) deficiency: considering the level of anemia, CRF patients have 
inappropriately low serum Epo levels due to abolished Epo gene expression (the prototypical 
hypoxia-sensitive gene) in the kidney [1]. 
Anemia dramatically reduces exercise tolerance, cognitive abilities, appetite and a number 
of other aspects of daily living subsumed within the concept of health-related quality of life 
(Hr-QoL). It also greatly increases morbidity and mortality, particularly cardiovascular. The 
only clinically relevant way of treating renal anemia is to enhance the signal that committed 
erythroid progenitors receive from the erythropoietin receptor (Epo-R). This signal promotes 
their survival and differentiation resulting in correction of anemia [1-3]. 
 
Erythropoisis stimulating agents: recombinant human erythropoietin and other approved 
treatments for renal anemia 
Stable expression of the human Epo gene in mammalian host cells was accomplished in 1985 
resulting in a pharmaceutical product containing recombinant human erythropoietin (rHu-
Epo). Decades of research preceding the actual production of rHu-Epo resulted in extensive 
understanding of (patho)physiology of Epo, CRF and the kidney-bone marrow 
communication that enabled rapid progress to clinical trials and a fast-track regulatory 
approval of rHu-Epo for treatment of renal anemia in the late 1980s [2,3]. The extensive use 
and research over the past 20 years resulted in great improvements in clinical use of rHu-
Epo in this setting, particularly regarding dosing, immediate therapeutic goal, i.e., target 
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hemoglobin (Hb) levels, and factors interfering with response to treatment. In the early days, 
rHu-Epo was delivered at high individual and total weekly doses by the intravenous (i.v.) 
route, three times a week (e.g., 3x10000 IU/kg/week i.v.) [4]. Subsequent research 
demonstrated that equal therapeutic effect (Hb control) could be achieved with much lower 
individual/total weekly doses (e.g., 3-fold lower), and with less frequent dosing, e.g., twice or 
once/week (not affecting drug utilization). It has been further demonstrated that 
subcutaneous (s.c.) administration (particularly convenient for patients not yet on dialysis) 
allows for further reduction in drug utilization (by 20-30%) with additional flexibility in 
dosing, showing equivalent therapeutic effect and drug utilization with thrice, twice or once 
a week dosing (tiw, biw, qw, respectively), or even with once every 2 weeks (q2w) or every 4 
weeks (q4w) dosing [5-7]. This flexibility allows for individualization of treatment in 
agreement with the (desired) therapeutic effect, rationalization of drug utilization and also 
contributes to lower occurrence of adverse effects [5-7]. The debate about the preferred Hb 
levels that should be achieved/maintained for the optimum short-term and long-term 
benefits is still on-going. The strongest evidence support the view that Hb levels in the range 
between 10 g/dL and 12-13 g/dL improve Hr-QoL and reduce the cardiovascular risk (as 
compared to lower Hb levels), whereas higher levels do not further improve immediate 
outcomes and increase the cardiovascular and cerebrovascular risk [8]. For patients starting 
treatment at Hb <10 g/dl, Hb increase should be gradual (e.g., not exceeding 1 g/dL/month) 
[9]. Optimizing the entire patient care contributes to a successful treatment, but keeping 
appropriate iron availability (to “fuel” the enhanced erythropoiesis) and controlling 
inflammation, as much as possible, are major factors contributing to the overall treatment 
success [9]. Accounting for these elements, rHu-Epo is very safe and highly effective in the 
vast majority of patients with marked immediate (anemia correction, Hr-QoL improvement) 
 5 
 
and long-term benefits (reduced morbidity/mortality), and with protective effects on the 
heart and the kidney [9]. 
Over the years, new treatments have emerged as alternatives to rHu-Epo for erythropoiesis 
stimulation, not only in renal anemia but also in other indications to which rHu-Epo has 
expanded (e.g., cancer, autologous blood donation; not subject of this paper). While there 
are numerous new molecules in various stages of development, two have been granted 
regulatory approvals at the turn of the millennium: darbepoetin alfa (initially named NESP, 
novel erythropoiesis stimulating protein) and CERA, continuous erythropoietin receptor 
activator. Both these molecules are Epo-analogues derived from rHu-Epo. Together with 
rHu-Epo they are called erythropoiesis stimulating agents (ESA) [10]. 
 
rHu-EPO 
Just as the endogenous hormone, rHu-Epo is a glycoprotein and hence not a single molecule 
but a family of isoforms: Epo gene encodes the protein part (165 amino acids), whereas 
glycosilation is a rather variable posttranslational process susceptible to various influences. 
The protein backbone has 4 sugar docking sites: 3 asparagins (Asn) for N-glycosilation and 1 
serine (Ser) for O-glycosilation. The variability of gylcosilation manifests as variable number 
of glycosilated docking sites and attached sugars vary in the number of branches (1 to 4 for 
N-sugars, 1-2 for O-sugars) and the content of sialic acid as the outermost sugar. The 
number of attached sugar chains, their branching and sialic acid content influence the mass 
and charge of the molecule. Hence, Epo is defined as a glycoprotein with Mw 30-34 kDa, 
where the protein part is 18.2 kDa and isoforms vary in mass and charge (“glycoforms”). The 
largest isoforms have all 4 docking sites occupied by sugars, all N-sugars are tetra-antennary 
and the O-sugar is di-antennary and they have 14 sialic acid residues; smaller isoforms are 
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consecutively less glycosilated and/or contain less branched sugars/sialic acid residues 
[2,11]. 
The “set” of isoforms output by an Epo producing cell depends on the expression/activity of 
glycosilation enzymes and this may vary. Relative composition of isoforms produced within 
one same individual may differ on daily basis or depending on (patho)physiological status 
[12]. rHu-Epo is a product of the human gene expressed in cultured mammalian cell lines 
that typically differ from endogenous human Epo-producing cells in respect to glycosilation 
pattern and its isoform profile could be distinguished from the circulating endogenous Epo 
[12]. Isoform composition in rHu-Epo is affected by the cell line, cell feeding process, 
harvesting, purification and other technological procedures [13]. 
The structure-activity relationship of (rHu)-Epo has been well established. The protein part 
forms the binding sites for Epo-R and is essential for biological activity. Sugars, however, 
have an important role. “Smaller and less acidic” isoforms (less N-sugars; less sialic acid) 
have higher affinity for Epo-R, whereas “larger and more acidic” ones have lower affinity for 
Epo-R. In vitro, erythropoietic potency of smaller isoforms is greater than that of larger 
isoforms. In fact, the core protein part (“naked Epo”) is the most potent. In vivo, however, 
the situation is completely opposite. Smaller isoforms, due to higher affinity, bind more 
tightly to Epo-R on erythroid progenitors in the bone marrow and are more susceptible to 
clearance by internalization of the Epo-Epo-R complex. Additionally, they are more 
susceptible to up-take and clearance by the asialo-glycoprotein receptor in the liver. Hence, 
their elimination half-life is very short and erythropoietic effect is weak (“naked Epo” is 
cleared within minutes and has no erythropoietic effect in vivo). Conversely, larger isoforms 
have longer circulating time and correspondingly more pronounced erythropoietic effect 
(circulating time compensates for reduced receptor affinity) [2,11,13]. 
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Extensive research in in vitro and animal models as well as human data clearly demonstrate 
that (rHu) Epo is a pluripotent hormone that directly affects a variety of tissues and cell 
types besides the erythropoietic lineage. It influences several intracellular signaling 
mechanisms and transcription factors; affects fundamental cellular events such as 
mitochondrial preservation, balance of the oxidant-antioxidant system, cell differentiation, 
proliferation and apoptosis; modifies inflammatory responses to various noxious stimuli and 
modulates the immune system by affecting activation of T-lymphocyte (sub)populations. 
Consequently, it has been implicated in tissue-repair and protection in various organs 
systems, e.g., the central nervous system and the cardiovascular system [14,15]. In this 
context, the smaller, erythropoietically less valuable isoforms, might have an important 
biological/pharmacological role. Specifically, the long-recognized organoprotective effect of 
Epo (rHu-Epo), initially ascribe solely to correction of anemia, can be separated from the 
anti-anemic effect [16]. Namely, besides the “classical” or “erythropoietic” Epo-R, in non-
hematological tissues Epo binds to another receptor structure. The tissue protective effects 
appear to require co-expression of Epo-R and CD131, a peptide structure (β-chain) that is a 
common element of the receptors for several cytokines and is called “beta common 
receptor” (βcR). Epo binds to an Epo-R-βcR complex. Activation results in inhibition of 
apoptosis and stimulated proliferation. Small Epo (rHu-Epo) isoforms bind with high affinity 
to Epo-R-βcR and in animal models display marked organoprotective effects (including 
neuroprotection) despite their extremely short half-life and no erythropoietic effect [16]. 
 
Darbepoetin alfa and CERA 
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Both molecules are direct Epo-R agonists and, although technologically and structurally 
different, both result from a concept that larger, longer-circulating molecules are preferred 
for erythropoiesis [10]. 
Development of darbepoetin was a direct extension of the knowledge about the role of 
sugars, particularly N-linked sugars in the Epo molecule. Human Epo-gene is point-mutated 
so that 5 amino acids in the rHu-Epo primary sequence are substituted – a manipulation 
allowing for insertion of two extra Asn residues, providing two extra N-sugar docking sites 
into the molecule. Hence, while rHu-Epo can have a maximum of 3 N-linked sugars and a 
total of 14 sialic acid residues, darbepoetin can have a maximum of 5 N-linked sugars and a 
total of 22 sialic acid residues. Consequently, while rHu-Epo is around 30 kDA (18.2 kDA 
protein + sugars), darbepoetin is a larger molecule (or a family of larger molecules/isoforms) 
with molecular mass of around 40 kDa (18.2 kDA protein + more sugars) [17]. In line with 
expectations, darbepoetin has considerably lower affinity for Epo-R than rHu-Epo, the 
ligand-receptor dissociation time is shorter and it is less potent in in vitro erythropoietic 
assasys (in some assays it behaves as a partial Epo-R agonist with lower affinity vs. rHu-Epo) 
[17,18]. On the other hand, its elimination is slower - human elimination half-life after i.v. 
injection is around 25 hours vs. around 8 hours for rHu-Epo – and it allows for a comparable 
effect on Hb but with less frequent administration [10,17]. 
CERA is pegylated rHu-Epo – large polyethyleneglycol (PEG) chains are added to the rHu-Epo 
molecule, so that molecular mass of CERA is 60 kDa (protein 18.2 kDA + 12.2 kDa sugars + 30 
kDa PEG). Its receptor affinity is further reduced, ligand-receptor dissociation time 
shortened, whereas elimination half-life is extended (around 130 hours in humans), allowing 
for further reduction in dosing frequency [19]. 
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In the pre-clinical development, neither drug showed any relevant distinction vs. rHu-Epo 
regarding toxicity/safety. The clinical data package resulting in approval of darbepoetin alfa 
comprised non-inferiority trials designed to show that it (i.v. or sc.; qw, q2w or q4w) 
corrected/maintained Hb level no worse than rHu-Epo with a comparable safety profile, but 
with less frequent dosing (rHu-Epo tiw or biw; i.v. or s.c.). Similarly, the CERA clinical data 
package comprised non-inferiority trials designed to show that the drug (q2w, q4w) 
corrected/maintained Hb no worse than rHu-Epo (tiw, biw or qw) or darbepoetin alfa (qw, 
q2w) but with less frequent dosing and with a comparable safety profile [10,17,19]. 
Based on their key clinical trials, darbepoetin alfa and CERA do not seem to relevantly differ 
from rHu-Epo in terms of their immediate effects and short-term benefits (anemia 
correction, Hr-QoL improvement) and safety/tolerability, but these compounds have never 
been soundly compared to rHu-Epo regarding long-term outcomes of the renal anemia 
treatment. 
 
Hypothesis 
As a treatment for renal anemia, rHu-Epo could be superior to darbepoetin alfa and CERA 
regarding long-term morbidity and mortality. Being a smaller and a more dynamic molecule 
(or a set of molecules) with a great flexibility of dosing on individual basis, it’s effect could be 
more manageable and appropriate for a tighter control of Hb within the desired range than 
in the case of the lager “more inert” molecules. Patients would experience less variability in 
Hb level over time – a factor suggested to impact the long-term outcomes [20,21]. Also, 
content of smaller and eryhtropoietically less valuable isoforms might be a factor 
contributing to greater direct organoprotective effects of rHu-Epo as compared to 
darbepoetin or CERA. 
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Observations supporting the hypothesis 
Two groups of observations support the stated hypothesis: a) detailed in vitro and animal 
studies in a variety of models indicate that the Epo-R-βcR-mediated organoprotective effect 
of Epo is mainly due to the action of “smaller”, less sialylated isoforms that have no 
practically relevant antianemic effect [16]; b) clinical trials and observational data indicate 
that rHu-Epo enables keeping Hb within the target range with less within-subject variability 
than darbepoetin alfa or CERA. Considering the latter, it should be noted that ESA-treated 
CRF patients experience the phenomenon of within-subject Hb oscillations that are more 
extensive than in patients not needing ESA treatment. The causes are not fully understood, 
but changes of ESA doses have an impact [22]. This is understandable since ESA dosing is 
based on titration according to the actual Hb level. Within-subject variability in Hb levels has 
been indicated as an independent predictor of mortality in CRF patients [20,21]. 
Two almost identically designed phase III darbepoetin randomized controlled trials (RCTs) 
compared it to rHu-Epo for Hb maintenance [23,24]: dialyzed patients with corrected Hb due 
to previous rHu-Epo treatment were randomized to continue rHu-Epo or to receive 
darbepoetin alfa. A 21-24-week dose-adjustment period was followed by an 8-week 
evaluation period. Data on within-subject variability are reported as a ratio of within-subject 
variances darbepoetin/rHu-Epo for the evaluation period. In the first trial [23], drugs were 
delivered i.v., rHu-Epo tiw (n=240) and darbepoetin qw (n=121), and Hb variability was by 
18% greater in the darbepoetin group (ratio 1.18, 95% CI 0.96-1.46). In the second trial [24] 
drugs were delivered either s.c. or i.v., rHu-Epo (n=112) tiw 46%, biw 34% and qw 20% and 
darbepoetin (n=224) qw 80% and q2w 20%. Ratio of within-subject variances for Hb levels 
was 1.03 (95% CI 0.86-1.24). Pooled estimate of the within-subject variance ratio from these 
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two trials obtained by a conventional meta-analytic technique is 1.09 (95% CI 0.95-1.26; 
p=0.207). 
Two identically designed phase III CERA RCTs compared it to rHu-Epo regarding Hb 
maintenance [25,26]: dialysis patients with corrected Hb (previous rHu-Epo treatment) were 
randomized to continue rHu-Epo or to receive CERA. A 28-week dose-adjustment period was 
followed by an 8-week evaluation period. Data on within-subject Hb variability are reported 
as mean±SD within-subject standard deviation for the titration and the evaluation period. In 
the first trial [25], drugs were delivered i.v., rHu-Epo (n=225) tiw 86%, biw 7% and qw7%, 
and CERA q2w (n=220) or q4w (n=221). Since q2w and q4w CERA regimens are considered 
equivalent, I present data for pooled CERA arms: variability during the 28-week titration 
period was higher with CERA (0.91±0.42 g/dL) than with rHu-Epo (0.79±0.43 g/dL) and the 
difference was statistically significant (0.12, 95% CI 0.05-0.18; p=0.001) indicating by 14% 
higher within-subject variability. No relevant differences were observed during the 8-week 
evaluation period. In the second trial [26] drugs were delivered s.c., rHu-Epo (n=191) tiw 
25%, biw 29% and qw 46% and CERA q2w (n=190) or q4w (n=191). Again, during the titration 
period variability was higher with CERA (0.85±0.42 g/dL) than with rHu-Epo (0.78±0.43 g/dL) 
with statistically borderline significant difference (0.07, 95% CI 0.00-0.14, p=0.06) indicating 
by 10% higher within-subject variability. No relevant differences were observed for the 
evaluation period. Combining these two studies by conventional meta-analytical technique 
indicates larger within-subject SD with CERA for the 28-week titration period: mean 
difference 0.10 g/dL (95% CI 0.05-0.15, p<0.001). 
This potential of rHu-Epo to provide Hb maintenance with less within-subject variability 
observed in strict phase III RCTs apparently translates into daily practice. In a recent study 
[27], patients from the Australian Renal Anemia Management database with corrected Hb 
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levels and at least 5 control Hb measurements over a 1-year period were retrospectively 
analyzed. There were 2596 patients on rHu-Epo and 1023 on darbepoetin, the two groups 
being comparable regarding age, sex, average Hb level at the beginning of the observational 
period and proportion of diabetics. Within-subject variance in Hb levels was significantly 
higher (p<0.001) in the darbepoetin group (by 24% higher; 95% CI 18-31). Another 
observational study embraced 6165 pre-dialysis CRF patients from Australia and several 
European countries that were followed-up for a minimum of 6 months and had at least 3 
repeated Hb measurements [21]. Patients needing ESA for Hb maintenance showed more 
within-subject variability in Hb than the patients not needing ESA treatment (as one would 
expect). Specifically, patients treated with rHu-EPO had higher odds of showing high 
variability than non-treated patients (OR 2.53, 95% CI 2.00-3.19), just as did patients treated 
with darbepoetin (OR 4.12, 95%CI 3.32-5.12) [21]. The report did not relate rHu-Epo-treated 
and darbepoetin-treated patients [21], but since both groups were compared to “no 
treatment” under similar conditions, an indirect comparison of rHu-Epo vs. darbepoetin is 
feasible 〈as exp[ln(OR rHu-EPO) – ln(OR darbepoetin)]〉. It indicates a considerably lower risk 
of high Hb variability (defined as within-subject SD >0.7 g/dL [21]) with rHu-Epo than with 
darbepoetin: OR 0.61 (95% CI 0.48-0.84). 
 
Consequences of the hypothesis and discussion 
Evaluation of the stated hypothesis seems to be a worthwhile effort. Due to the high 
incidence and prevalence of CRF and improvements in the overall care for these patients 
that have prolonged their life-expectancy, anemia management has turned into a long-term 
therapy. Under such conditions, effects that would otherwise be considered as minor would 
yield considerable actual benefits. For example, absolute risk reduction regarding mortality 
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over a 2-year period as low as 0.5% would, in absolute terms, mean thousands of saved lives. 
Combined with potentially reduced morbidity and hospitalizations, it would represent a 
considerable healthcare and pharmacoeconomic benefit. 
Well designed clinical experiments (RCTs) comparing rHu-Epo and darbepoetin and/or CERA 
for long-term “hard” outcomes (cardiovascular and all-cause moribidity and mortality) would 
be needed for evaluation of the hypothesis. Using Hb variability as a surrogate outcome 
would not be appropriate. Although some epidemiological data suggest it as a predictor of 
poor long-term outcomes, the relationship between Hb variability and morbidity and 
mortality in CRF patients needs yet to be characterized. Furthermore, the hypothesized 
difference between rHu-Epo and darbepoetin or CERA might not be due solely to the ability 
of less variable Hb control. On the other hand, trials based on surrogate cardiovascular or 
renal markers (e.g., left ventricular mass/remodeling or ejection fraction, renal function) 
would not fully suffice, as they may not be fully predictive of the hard outcomes and they 
may not evaluate all possible differences between treatments relevant for the outcomes of 
interest. 
Performing such trials would be logistically highly demanding. The trials would need to be 
long, sequential (for a timely recognition of an effect) and large (to ascertain the needed 
power). Also, a number of confounding factors would need to be considered, particularly the 
existing cardiovascular burden and related interventions, likely requesting stratified 
randomization. Considering that data exclusivity and patent protection for proprietary rHu-
Epo has already expired (e.g., in the EU) or is about to expire (e.g., in the USA), it does not 
seem likely that pharmaceutical industry would have any interest in sponsoring such trials 
and it does not seem likely that such trials would ever be performed. An alternative 
approach could include meta-analysis of the existing comparative trials, particularly 
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individual patient data meta-analysis that could account for the starting patients’ 
cardiovascular burden and other comorbidity, as well as for potential differences in targeted 
Hb levels in different trials. However, if faces two obstacles: the number of comparative 
trials is small and there seems to be no trial longer than 1 year. Therefore, under the 
circumstances, minutely planned stratified observational studies appear to be the only 
realistic and most feasible approach for evaluation of the stated hypothesis. 
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